Posted by Michael Wonder on 05 Oct 2021
Heron Therapeutics announces filing of a supplemental new drug application for significant expansion of Zynrelef indication statement based on successful outcome of FDA type C meeting
4 October 2021 - FDA agreed to the immediate filing of supplemental new drug application to significantly expand the Zynrelef indication statement based on previously submitted data with no new clinical studies.
Heron Therapeutics today announced submission of a supplemental new drug application for Zynrelef (bupivacaine and meloxicam) extended release solution for an expanded indication.
